- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
![]()
PLAY BUTTON
![]()
PLAY BUTTON
![]()
42 Cards in this Set
- Front
- Back
|
what kind of cells have Rc for HIV virus
|
macrophages
dendritic cells t cells |
|
what are the co-receptors for HIV
|
CCR5
CXCR-4 |
|
what are the viral proteins in HIV and what is the name of the complex
|
gp41
gp120 they form the complex gp 160 |
|
how does the HIV virus attach onto the cells
|
binds to CD4
then binds to CCR5 early in the infection then binds CXCR-4 later on in the infection |
|
what is viral tropism
|
the preference for certain types of cells
herpes: nerve cells t-cell tropic virus CD4+CXCR-4 or CD4+CXCR-4+CCR-5 monocyte tropic virus CDR4 + CCR5 or CD4+CXCR-4+CCR-5 |
|
how does HIV manage to fuse onto the virus
|
requires HR2 and HR1 proteins
gp41 contains HR2 (and HR1) which unfolds to reveal a hydrophobic segment which inserts itself into the cell membrane |
|
what does Reverse transcriptase do
|
makes a DNA copy out of RNA
HIV's polymerase will then copy the DNA made to form a double stranded DNA |
|
what are the steps in the synthesis of viral HIV proteins
|
virus enters cell
RTase converts the RNA into DNA DNA becomes dbl stranded via polmerase viral DNA inserted into cell DNA via integrase once cell makes message, viral protease will come and cut out the useful proteins |
|
what are the drug targets of HIV
|
protease
RTase inegrase |
|
what is the state of a virus in a G1 cell
|
latent
|
|
what is the state of a virus in a G0 cell
|
G0 cell does not support infection or allow for the incorporation of viral DNA
|
|
what are the classes of inhibitors for RTase
|
nucleoside inhibitors
non nucleoside inhibitors |
|
what is the MOA of nucleoside inhibitors
|
bind to RTase by going to the active site and stops the production of viral DNA from RNA
|
|
what is the MOA of nonnucleoside inhibitors
|
NON COMPETITIVE INHIBITORS
DON'T BIND TO THE ACTIVE SITE OF RTase but bind else where inhibit RTase activity by reducing the affinity of RTase for RNA thereby stopping viral DNA production from RNA |
|
what are the properties of the NRTIs, NtRTIs
NUCLEOSIDE INHIBITORS |
prodrug (becomes active via cellular kinase)
some drugs accumulate if cell is latent cause chain termination (due to lack of 3'OH) less affinity for cellular DNA polymerase but may effect mitochondria DNA polymerase |
|
what is an adverse effect of NRTIs, NtRTIs
|
bone marrow suppression
|
|
what drugs are part of the HAART regiment
|
NtRTIs
NRTIs |
|
why can't drugs that become active via TK effect HIV virus
|
because TK is specefic for only herpes
|
|
what are the Thymidine analogs (VUDINE) and what phosphorylates them
|
ziduovudine
stavudine phosphorylated via TTPs |
|
what are the cytosine analogs
|
emtricitabine
lamivudine phosphorylated by cellular kinase |
|
what are the adenosine analogs
|
didanosine
tenofovir didanosine is phosphorylated to triphosphate form by cellular kinase tenofovir already has a phosphate and only gains 2 from the cellular kinase |
|
what are the guanosine analogs
|
abacavir (carbocyclic purine)
|
|
what is the MOA of guanosine analogs of NRTIs
|
abacavir
potent inhibitor of RTase MOA: chain termination |
|
what is the side effect of guanosine analogs
|
hypersensitivity reaction
|
|
what are the NNRTIs
|
nevirapine
delavirdine efavirenz etravirine |
|
what is the oral bioavalability, metabolism, and drug interactions of the NNRTIs
|
good oral bioavailability
hepatic metabolism lots of drug interactions but less for nevirapine |
|
if you're resistant to nevirapine, or delaviridine, or efavirenze what can you give the pt
|
etravirine
|
|
why are you able to give Etravirine if someone is resistant to Efravirenz
|
due the etravirine being structurally flexible that even after the mutation it will still have good affinity for RTase
reserved use |
|
what is the most common adverse reaction w/ NNRTI (non nueclosides)
|
rash
|
|
do NNRTI's (nonnucleoside inhibitors) induce cytochroms
|
yes
|
|
what are the properties of the protease inhibitors and what is the MOA
|
peptidomimetic
prevent the processing of long viral protein |
|
what is the adverse effect of protease inhibitors
|
lipodystrophy (seen in cusshings)
|
|
what are the protease inhibitors
|
atazanavir
indinavir nelfinavir ritonavir darunavir lopinavir tipranavir saquinavir end in NAVIR |
|
atazanavir CYP3A4
|
metabolized
|
|
indinavir CYP3A4
|
inducer
|
|
ritonavir CYP3A4
|
inhibitor
|
|
saquinavir CYP3A4
|
inducer
|
|
what drugs are given w/ ritonavir
|
darunavir
lopinavir tipranavir all of these are extensively metabolized by CYP3A4 and one major use of ritonavir is to keep other drugs from being extensively metabolized by CYP3A4 |
|
what are the entry inhibitors
|
Enfuvirtide
Maraviroc |
|
what is the MOA of entry inhibitors
|
Enfuviritide
block viral absorption and block viral entry into CD4+ lymphocytes they mimic HR2 region of gp41 to prevent viral fusion to membrane |
|
what are the co-receptor antagonist (entry inhibitor)
|
maraviroc
|
|
how does Maraviroc work
|
co-Rc antagonist
CCR5 Rc antagonist thereby blocking ability of virus to bind to CCR5 Rc |